Wockhardt Limited (NSE:WOCKPHARMA)
1,320.30
+51.10 (4.03%)
Mar 10, 2026, 1:50 PM IST
Wockhardt Revenue
Wockhardt had revenue of 8.88B INR in the quarter ending December 31, 2025, with 23.16% growth. This brings the company's revenue in the last twelve months to 31.74B, up 5.76% year-over-year. In the fiscal year ending March 31, 2025, Wockhardt had annual revenue of 30.35B with 7.24% growth.
Revenue (ttm)
31.74B
Revenue Growth
+5.76%
P/S Ratio
6.50
Revenue / Employee
13.82M
Employees
2,296
Market Cap
206.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 30.35B | 2.05B | 7.24% |
| Mar 31, 2024 | 28.30B | 1.73B | 6.51% |
| Mar 31, 2023 | 26.57B | -5.73B | -17.74% |
| Mar 31, 2022 | 32.30B | 5.22B | 19.28% |
| Mar 31, 2021 | 27.08B | -1.36B | -4.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ipca Laboratories | 95.06B |
| Piramal Pharma | 88.71B |
| Emcure Pharmaceuticals | 88.50B |
| Alembic Pharmaceuticals | 72.67B |
| Gland Pharma | 61.13B |
| Ajanta Pharma | 52.02B |
| Strides Pharma Science | 47.26B |
| NATCO Pharma | 45.63B |
Wockhardt News
- 4 days ago - Pharma sector stocks today, March 6: Shilpa Medicare surge 3.08%, Wockhardt jumps 2.12%, Natco Pharma up 1.84%, - Business Upturn
- 6 weeks ago - Wockhardt shares in focus after Phase 3 success of novel antibiotic Foviscu - Business Upturn
- 2 months ago - Wockhardt files Marketing Authorisation Application to EMA for antibiotic WCK 5222 - Business Upturn
- 2 months ago - Wockhardt shares in spotlight after EMA grants accelerated assessment to WCK 5222 - Business Upturn
- 3 months ago - Wockhardt shares rally sharply over 9% as US FDA accepts NDA for breakthrough antibiotic Zaynich - Business Upturn
- 3 months ago - Wockhardt secures historic US FDA acceptance for antibiotic Zaynich - Business Upturn
- 5 months ago - Wockhardt submits NDA to US FDA for novel antibacterial Zidebactam-Cefepime - Business Upturn
- 5 months ago - Wockhardt shares fall over 5% after Trump’s pharma tariff announcement - Business Upturn